The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Antivenom-Global Market Insights and Sales Trends 2025
Synopsis
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings. They are only recommended if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the species involved. It is given by injection.
The global Antivenom market size is expected to reach US$ 1283.7 million by 2029, growing at a CAGR of 4.2% from 2023 to 2029. The market is mainly driven by the significant applications of Antivenom in various end use industries. The expanding demands from the Non-profit Institutions and Hospitals and Clinic, are propelling Antivenom market. Polyvalent antivenom, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Monovalent antivenom segment is estimated at % CAGR for the next seven-year period.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Antivenom, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Antivenom market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Antivenom market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Antivenom sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Antivenom covered in this report include CSL, Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts and Bharat Serums and Vaccines, etc.
The global Antivenom market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Global Antivenom market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Antivenom market, Segment by Type:
Polyvalent antivenom
Monovalent antivenom
Global Antivenom market, by Application
Non-profit Institutions
Hospitals and Clinic
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Antivenom manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Antivenom in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings. They are only recommended if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the species involved. It is given by injection.
The global Antivenom market size is expected to reach US$ 1283.7 million by 2029, growing at a CAGR of 4.2% from 2023 to 2029. The market is mainly driven by the significant applications of Antivenom in various end use industries. The expanding demands from the Non-profit Institutions and Hospitals and Clinic, are propelling Antivenom market. Polyvalent antivenom, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Monovalent antivenom segment is estimated at % CAGR for the next seven-year period.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Antivenom, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Antivenom market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Antivenom market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Antivenom sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Antivenom covered in this report include CSL, Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts and Bharat Serums and Vaccines, etc.
The global Antivenom market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Global Antivenom market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Antivenom market, Segment by Type:
Polyvalent antivenom
Monovalent antivenom
Global Antivenom market, by Application
Non-profit Institutions
Hospitals and Clinic
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Antivenom manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Antivenom in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Antivenom Market Overview
1.1 Antivenom Product Overview
1.2 Antivenom Market Segment by Type
1.2.1 Polyvalent antivenom
1.2.2 Monovalent antivenom
1.3 Global Antivenom Market Size by Type
1.3.1 Global Antivenom Market Size Overview by Type (2018-2029)
1.3.2 Global Antivenom Historic Market Size Review by Type (2018-2023)
1.3.3 Global Antivenom Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Antivenom Sales Breakdown by Type (2018-2023)
1.4.2 Europe Antivenom Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Antivenom Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Antivenom Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Antivenom Sales Breakdown by Type (2018-2023)
2 Global Antivenom Market Competition by Company
2.1 Global Top Players by Antivenom Sales (2018-2023)
2.2 Global Top Players by Antivenom Revenue (2018-2023)
2.3 Global Top Players by Antivenom Price (2018-2023)
2.4 Global Top Manufacturers Antivenom Manufacturing Base Distribution, Sales Area, Product Type
2.5 Antivenom Market Competitive Situation and Trends
2.5.1 Antivenom Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Antivenom Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antivenom as of 2022)
2.7 Date of Key Manufacturers Enter into Antivenom Market
2.8 Key Manufacturers Antivenom Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Antivenom Status and Outlook by Region
3.1 Global Antivenom Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Antivenom Historic Market Size by Region
3.2.1 Global Antivenom Sales in Volume by Region (2018-2023)
3.2.2 Global Antivenom Sales in Value by Region (2018-2023)
3.2.3 Global Antivenom Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Antivenom Forecasted Market Size by Region
3.3.1 Global Antivenom Sales in Volume by Region (2024-2029)
3.3.2 Global Antivenom Sales in Value by Region (2024-2029)
3.3.3 Global Antivenom Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Antivenom by Application
4.1 Antivenom Market Segment by Application
4.1.1 Non-profit Institutions
4.1.2 Hospitals and Clinic
4.2 Global Antivenom Market Size by Application
4.2.1 Global Antivenom Market Size Overview by Application (2018-2029)
4.2.2 Global Antivenom Historic Market Size Review by Application (2018-2023)
4.2.3 Global Antivenom Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Antivenom Sales Breakdown by Application (2018-2023)
4.3.2 Europe Antivenom Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Antivenom Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Antivenom Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Antivenom Sales Breakdown by Application (2018-2023)
5 North America Antivenom by Country
5.1 North America Antivenom Historic Market Size by Country
5.1.1 North America Antivenom Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Antivenom Sales in Volume by Country (2018-2023)
5.1.3 North America Antivenom Sales in Value by Country (2018-2023)
5.2 North America Antivenom Forecasted Market Size by Country
5.2.1 North America Antivenom Sales in Volume by Country (2024-2029)
5.2.2 North America Antivenom Sales in Value by Country (2024-2029)
6 Europe Antivenom by Country
6.1 Europe Antivenom Historic Market Size by Country
6.1.1 Europe Antivenom Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Antivenom Sales in Volume by Country (2018-2023)
6.1.3 Europe Antivenom Sales in Value by Country (2018-2023)
6.2 Europe Antivenom Forecasted Market Size by Country
6.2.1 Europe Antivenom Sales in Volume by Country (2024-2029)
6.2.2 Europe Antivenom Sales in Value by Country (2024-2029)
7 Asia-Pacific Antivenom by Region
7.1 Asia-Pacific Antivenom Historic Market Size by Region
7.1.1 Asia-Pacific Antivenom Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Antivenom Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Antivenom Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Antivenom Forecasted Market Size by Region
7.2.1 Asia-Pacific Antivenom Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Antivenom Sales in Value by Region (2024-2029)
8 Latin America Antivenom by Country
8.1 Latin America Antivenom Historic Market Size by Country
8.1.1 Latin America Antivenom Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Antivenom Sales in Volume by Country (2018-2023)
8.1.3 Latin America Antivenom Sales in Value by Country (2018-2023)
8.2 Latin America Antivenom Forecasted Market Size by Country
8.2.1 Latin America Antivenom Sales in Volume by Country (2024-2029)
8.2.2 Latin America Antivenom Sales in Value by Country (2024-2029)
9 Middle East and Africa Antivenom by Country
9.1 Middle East and Africa Antivenom Historic Market Size by Country
9.1.1 Middle East and Africa Antivenom Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Antivenom Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Antivenom Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Antivenom Forecasted Market Size by Country
9.2.1 Middle East and Africa Antivenom Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Antivenom Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 CSL
10.1.1 CSL Company Information
10.1.2 CSL Introduction and Business Overview
10.1.3 CSL Antivenom Sales, Revenue and Gross Margin (2018-2023)
10.1.4 CSL Antivenom Products Offered
10.1.5 CSL Recent Development
10.2 Merck
10.2.1 Merck Company Information
10.2.2 Merck Introduction and Business Overview
10.2.3 Merck Antivenom Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Merck Antivenom Products Offered
10.2.5 Merck Recent Development
10.3 BTG
10.3.1 BTG Company Information
10.3.2 BTG Introduction and Business Overview
10.3.3 BTG Antivenom Sales, Revenue and Gross Margin (2018-2023)
10.3.4 BTG Antivenom Products Offered
10.3.5 BTG Recent Development
10.4 Pfizer
10.4.1 Pfizer Company Information
10.4.2 Pfizer Introduction and Business Overview
10.4.3 Pfizer Antivenom Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Pfizer Antivenom Products Offered
10.4.5 Pfizer Recent Development
10.5 Haffkine Bio-Pharmaceutical
10.5.1 Haffkine Bio-Pharmaceutical Company Information
10.5.2 Haffkine Bio-Pharmaceutical Introduction and Business Overview
10.5.3 Haffkine Bio-Pharmaceutical Antivenom Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Haffkine Bio-Pharmaceutical Antivenom Products Offered
10.5.5 Haffkine Bio-Pharmaceutical Recent Development
10.6 Rare Disease Therapeutics
10.6.1 Rare Disease Therapeutics Company Information
10.6.2 Rare Disease Therapeutics Introduction and Business Overview
10.6.3 Rare Disease Therapeutics Antivenom Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Rare Disease Therapeutics Antivenom Products Offered
10.6.5 Rare Disease Therapeutics Recent Development
10.7 Flynn Pharma
10.7.1 Flynn Pharma Company Information
10.7.2 Flynn Pharma Introduction and Business Overview
10.7.3 Flynn Pharma Antivenom Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Flynn Pharma Antivenom Products Offered
10.7.5 Flynn Pharma Recent Development
10.8 Vins Bioproducts
10.8.1 Vins Bioproducts Company Information
10.8.2 Vins Bioproducts Introduction and Business Overview
10.8.3 Vins Bioproducts Antivenom Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Vins Bioproducts Antivenom Products Offered
10.8.5 Vins Bioproducts Recent Development
10.9 Bharat Serums and Vaccines
10.9.1 Bharat Serums and Vaccines Company Information
10.9.2 Bharat Serums and Vaccines Introduction and Business Overview
10.9.3 Bharat Serums and Vaccines Antivenom Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Bharat Serums and Vaccines Antivenom Products Offered
10.9.5 Bharat Serums and Vaccines Recent Development
10.10 Serum Biotech
10.10.1 Serum Biotech Company Information
10.10.2 Serum Biotech Introduction and Business Overview
10.10.3 Serum Biotech Antivenom Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Serum Biotech Antivenom Products Offered
10.10.5 Serum Biotech Recent Development
10.11 MicroPharm
10.11.1 MicroPharm Company Information
10.11.2 MicroPharm Introduction and Business Overview
10.11.3 MicroPharm Antivenom Sales, Revenue and Gross Margin (2018-2023)
10.11.4 MicroPharm Antivenom Products Offered
10.11.5 MicroPharm Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Antivenom Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Antivenom Industrial Chain Analysis
11.4 Antivenom Market Dynamics
11.4.1 Antivenom Industry Trends
11.4.2 Antivenom Market Drivers
11.4.3 Antivenom Market Challenges
11.4.4 Antivenom Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Antivenom Distributors
12.3 Antivenom Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
